CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tensha Therapeutics announced today it has begun the first clinical trial of its small molecule, bromodomain and extra-terminal domain (BET) bromodomain ...

Inhibiting the functionality of the bromodomain 1 (BD1) subunit of BET proteins is believed to disrupt homeostatic gene regulation. This can lead to potential clinical safety concerns such as ...

Bromodomain and extraterminal domain (BET) Inhibitors are small molecule inhibitors which have proliferating properties. The bromodomain and extraterminal domain (BET) inhibitors have ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two ...

Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and development of the Bromodomain and Extraterminal Domain (BET) Inhibitors Market.

Sep 12, 2011 (BUSINESS WIRE) -- Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for ...

Detailed price information for Resverlogix Corp (RVX-T) from The Globe and Mail including charting and trades.

Under the terms of the agreement, Medivation shall have access to OncoFusion's growing library of small molecule BET bromodomain inhibitor compounds from which Medivation may select compounds to ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accepted for poster ...